Other substances

Cangrelor

A P2Y12 inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

4
 Supporting references
0
 Contradictory references
4
 AI-suggested references
0
 Clinical trials

General information

Cangrelor is an anti-clotting nucleoside triphosphate analogue. It functions as a P2Y12 receptor antagonist (ChEBI).

Cangrelor on DrugBank
Cangrelor on PubChem
Cangrelor on Wikipedia

Synonyms

ZINC000085537017

Marketed as

KENGREAL; KENGREXAL

 

Structure image - Cangrelor

CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O

Supporting references

Link Tested on Impact factor Notes Publication date
Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study
in silico 3.31

In silico screening of NSP16 (viral methyltrasferase) inhibitors.

 Aug/03/2020
Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
Preprint Screening 		in vitro

inhibitor of the ACE2-RBD interaction

 Jun/16/2020
Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2
Spike protein ACE2 Small molecule In silico 		in silico 2.08

Predicted to inhibit the interaction between the SARS-CoV-2 spike protein domain S1 and the host ACE2 receptor.

 Aug/21/2020
Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13)
nsp13 Small molecule In silico 		in silico 5.16

Predicted to inhibit the SARS-CoV-2 nsp13 helicase (both wild type and with C17747T and A17858G mutations).

 Sep/24/2020

AI-suggested references

Link Publication date
Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2
Aug/03/2020
Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a pro-thrombotic stimulus for platelets
May/24/2020
Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective
Sep/12/2021
Multi-conformation representation of Mpro identifies promising candidates for drug repurposing against COVID-19
Apr/17/2021
Export (.csv)